Peptide vaccination directed against IDO1-expressing immune cells elicits CD8 + and CD4 + T-cell-mediated antitumor immunity and enhanced anti-PD1 responses.

MLA

Dey, Souvik, et al. “Peptide Vaccination Directed against IDO1-Expressing Immune Cells Elicits CD8 + and CD4 + T-Cell-Mediated Antitumor Immunity and Enhanced Anti-PD1 Responses.” Journal for Immunotherapy of Cancer, vol. 8, no. 2, July 2020. EBSCOhost, https://doi.org/10.1136/jitc-2020-000605.

APA

Dey, S., Sutanto-Ward, E., Kopp, K. L., DuHadaway, J., Mondal, A., Ghaban, D., Lecoq, I., Zocca, M.-B., Merlo, L. M. F., Mandik-Nayak, L., Andersen, M. H., Pedersen, A. W., & Muller, A. J. (2020). Peptide vaccination directed against IDO1-expressing immune cells elicits CD8 + and CD4 + T-cell-mediated antitumor immunity and enhanced anti-PD1 responses. Journal for Immunotherapy of Cancer, 8(2). https://doi.org/10.1136/jitc-2020-000605

Chicago

Dey, Souvik, Erika Sutanto-Ward, Katharina L Kopp, James DuHadaway, Arpita Mondal, Dema Ghaban, Inés Lecoq, et al. 2020. “Peptide Vaccination Directed against IDO1-Expressing Immune Cells Elicits CD8 + and CD4 + T-Cell-Mediated Antitumor Immunity and Enhanced Anti-PD1 Responses.” Journal for Immunotherapy of Cancer 8 (2). doi:10.1136/jitc-2020-000605.